MicroRNA (miRNA) dysfunction plays a critical role in neurodegenerative diseases by disrupting gene expression patterns essential for neuronal survival, synaptic function, and protein homeostasis. miRNAs are small non-coding RNAs that regulate gene expression post-transcriptionally by binding to target mRNAs and inhibiting their translation or promoting degradation. Dysregulated miRNA expression is implicated in Alzheimer's disease, Parkinson's disease, amyotrophic lateral sclerosis, and Huntington's disease .
- Primary miRNA (pri-miRNA): Transcribed by RNA polymerase II as long transcripts
- Drosha: Nuclear RNase III enzyme cleaves pri-miRNA to pre-miRNA
- DGCR8: Essential co-factor for Drosha processing
- Exportin-5: Transports pre-miRNA to cytoplasm
- Dicer: Cytoplasmic RNase III cleaves pre-miRNA to mature miRNA duplex
- TRBP: Dicer co-factor for processing
- Argonaute (AGO) proteins: Core component of RNA-induced silencing complex (RISC)
- GW182: Mediates translational repression and deadenylation
- Target mRNA recognition: 6-8 nucleotide seed region determines specificity
miR-9 is crucial for neuronal development and function:
- Target genes: REST, FOXG1, and Notch signaling components
- Alzheimer's disease: Reduced in AD hippocampus and cortical regions
- Parkinson's disease: Dysregulated in substantia nigra
- Function: Maintains neuronal identity, regulates synaptic plasticity
miR-124 is the most abundant neuron-specific miRNA:
- Target genes: PTBP1, REST, and synaptic proteins
- Alzheimer's disease: Promotes BACE1 expression, affects APP processing
- Parkinson's disease: Modulates α-synuclein expression
- Function: Neuronal differentiation, synaptic formation
miR-29 family (miR-29a, b, c) is important for neuronal health:
- Target genes: BACE1, DNMT3A, and anti-apoptotic proteins
- Alzheimer's disease: Decreased in AD brains, leads to increased BACE1
- ALS: Reduced in motor neurons, affects TDP-43 pathology
- Function: Regulates apoptosis, DNA methylation
miR-153 targets α-synuclein and BACE1:
- Target genes: SNCA, BACE1
- Alzheimer's disease: Decreased, contributing to BACE1 upregulation
- Parkinson's disease: Reduced, leading to α-synuclein accumulation
- Function: Direct regulation of neurodegeneration genes
- Transcription factor alterations: REST dysfunction in AD affects neuronal miRNA expression
- Epigenetic modifications: DNA methylation of miRNA promoters
- Aging: Global miRNA expression changes with age
- Dicer dysfunction: Reduced Dicer in AD and PD brains
- Exportin-5 impairment: Affects pre-miRNA nuclear export
- AGO2 modifications: Oxidative stress affects RISC function
- Single nucleotide polymorphisms (SNPs): In miRNA binding sites alter targeting
- RNA-binding proteins: Compete for mRNA binding
- Circular RNAs (circRNAs): Act as miRNA sponges
| miRNA |
Change |
Target |
Function |
| miR-9 |
↓ |
BACE1 |
Amyloid processing |
| miR-29 |
↓ |
BACE1 |
Amyloid processing |
| miR-124 |
↑ |
BACE1 |
Amyloid processing |
| miR-146a |
↑ |
TRAF6 |
Neuroinflammation |
| miR-155 |
↑ |
SOCS1 |
Neuroinflammation |
| miRNA |
Change |
Target |
Function |
| miR-7 |
↓ |
α-synuclein |
Protein aggregation |
| miR-124 |
↓ |
DJ-1, BAX |
Neuroprotection |
| miR-153 |
↓ |
α-synuclein |
Protein aggregation |
| miR-29 |
↓ |
SNCA |
Protein aggregation |
| miR-184 |
↓ |
GLUT4 |
Energy metabolism |
| miRNA |
Change |
Target |
Function |
| miR-155 |
↑ |
C9orf72 |
RNA toxicity |
| miR-29 |
↓ |
SOD1 |
Motor neuron survival |
| miR-23a |
↓ |
PGC-1α |
Mitochondrial function |
| miR-218 |
↓ |
SOD1, VGF |
Motor neuron function |
- miR-9 mimics: Under development for AD treatment
- miR-29 mimics: Potential for BACE1 reduction
- miR-7 mimics: Protect against α-synuclein toxicity
- Anti-miR-155: In clinical trials for ALS and neuroinflammation
- Anti-miR-146a: Reduces neuroinflammation in AD models
- Anti-miR-124: Under investigation for PD
- Valproic acid: Increases miR-9 expression
- HDAC inhibitors: Modulate miRNA transcription
- Natural compounds: Curcumin, resveratrol affect miRNA expression
- AAV-miRNA: Targeted delivery of miRNA mimics/inhibitors
- Lenti-miRNA: Transient modulation of miRNA levels
- Exosome delivery: Natural miRNA delivery vehicles
¶ Diagnostic and Biomarker Potential
- miR-27a, miR-29c: Elevated in AD CSF
- miR-153, miR-409-3p: Reduced in PD CSF
- miR-219: ALS-specific changes
- miR-132: AD blood biomarker
- miR-153, miR-223: PD blood markers
- miR-206: ALS progression marker
- Single-cell miRNA sequencing to understand cell-type specific changes
- miRNA delivery systems using lipid nanoparticles and exosomes
- CRISPR-Cas13 based miRNA editing
- Personalized miRNA signatures for neurodegenerative diseases
- Multi-omi approaches integrating miRNA with proteomics and metabolomics
This section highlights recent publications relevant to this mechanism.